According to pre-clinical and clinical data certain cytotoxic therapies +/− immunomodulating agents, including e.g. the GILF (gemcitabine, irinotecan, levofolinic, and 5-fluorouracil), GILFI (gemcitabine, irinotecan, levofolinic acid, fluorouracil, aldesleukin), and GOLFIG (gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, GM-CSF, aldesleukin) regimens, have the ability to effectively up-regulate EGFR expression on colon cancer cells, thereby enhancing the sensitivity of the colon cancer cells to cetuximab-mediated ADCC [12]–[14]. The gene discussed is IL2; the disease is malignant colon neoplasm.